ORIC Pharmaceuticals, Inc. (ORIC): History, Ownership, Mission, How It Works & Makes Money

In the complex world of oncology, how does ORIC Pharmaceuticals, Inc. (ORIC) stand out as a clinical-stage biopharmaceutical company dedicated to improving patients' lives? With a focus on overcoming resistance in cancer, ORIC has a pipeline of therapies targeting hormone-dependent cancers, precision oncology, and key tumor dependencies. Recent achievements, including strategic partnerships and securing $125 million in financing, extend their cash runway into late 2026, positioning them for potential registration studies for ORIC-114 and ORIC-944. Keep reading to explore ORIC's history, ownership, mission, and how it operates and generates revenue.

ORIC Pharmaceuticals, Inc. (ORIC) History

ORIC Pharmaceuticals, Inc. Founding Timeline

Year established

ORIC Pharmaceuticals was founded in 2014.

Original location

The company is headquartered in South San Francisco, California.

Founding team members

The founding team included:

• Charles Sawyers
• Scott Lowe
• Kevan Shokat
• Jay Bradner

Initial capital/funding

In October 2016, ORIC Pharmaceuticals completed a Series A financing round, securing $50 million. This funding was led by Foresite Capital, with significant participation from Taiho Ventures, Boxer Capital, and Alexandria Venture Investments.

ORIC Pharmaceuticals, Inc. Evolution Milestones

ORIC Pharmaceuticals, Inc. Transformative Moments

• Securing Series A and B Financing: These funding rounds provided substantial capital to advance research and development efforts, enabling the company to expand its pipeline and initiate clinical trials.
• Acquisition of Voronoi's HCC4006 program: This strategic acquisition broadened ORIC's portfolio, adding a promising drug candidate targeting a specific resistance mechanism in lung cancer.
• Initial Public Offering (IPO): The IPO in 2020 marked a significant milestone, providing the financial resources needed to accelerate clinical development programs and support long-term growth.
• Focus on Precision Oncology: ORIC's emphasis on developing therapies that target specific resistance mechanisms and utilizing biomarker-driven patient selection has been a transformative approach, potentially improving treatment outcomes and personalizing cancer care.

For further insights into the company's guiding principles, explore: Mission Statement, Vision, & Core Values of ORIC Pharmaceuticals, Inc. (ORIC).

ORIC Pharmaceuticals, Inc. (ORIC) Ownership Structure

ORIC Pharmaceuticals, Inc. features a mix of institutional, insider, and retail ownership, shaping its governance and strategic direction.

ORIC's Current Status

ORIC Pharmaceuticals, Inc. is a publicly traded company, listed on the stock market under the ticker symbol ORIC. This allows individuals and institutions to invest in the company's stock, influencing its market capitalization and providing capital for its operations and growth.

ORIC's Ownership Breakdown

ORIC Pharmaceuticals' ownership is distributed among various shareholders, including institutional investors, company insiders, and retail investors. The following table summarizes the ownership breakdown:

ORIC's Leadership

ORIC Pharmaceuticals is guided by a team of experienced leaders. Key members of the leadership team include:

• Jacob Chacko, M.D.: President and Chief Executive Officer
• Dominick Fischetti: Chief Financial Officer
• Scott্যান Crawford, M.D., Ph.D.: Chief Medical Officer

Understanding the ownership structure and leadership provides insights into the company's governance and strategic decision-making processes. To gain more insights into who is investing in ORIC Pharmaceuticals and the reasons behind their investment decisions, check out this resource: Exploring ORIC Pharmaceuticals, Inc. (ORIC) Investor Profile: Who’s Buying and Why?

ORIC Pharmaceuticals, Inc. (ORIC) Mission and Values

ORIC Pharmaceuticals is dedicated to fighting cancer by developing innovative therapies that address resistance mechanisms. The company values scientific rigor, patient-centricity, and a collaborative spirit in its pursuit of groundbreaking treatments.

ORIC Pharmaceuticals' Core Purpose

Official mission statement

ORIC Pharmaceuticals' mission statement is: 'To develop and commercialize therapies that overcome resistance in cancer.'

• Focuses on creating treatments that specifically target and overcome resistance mechanisms in cancer.
• Aims to bring these therapies to market, ensuring they reach patients in need.
• Reflects a commitment to innovation and addressing unmet needs in cancer treatment.

Vision statement

While ORIC Pharmaceuticals does not have a prominently publicized vision statement, their actions and focus suggest a vision centered on:

• Becoming a leader in the development of resistance-overcoming cancer therapies.
• Significantly improving outcomes for cancer patients through targeted and innovative treatments.
• Building a sustainable company driven by scientific excellence and a commitment to patients.

Company slogan/tagline

ORIC Pharmaceuticals does not have a widely recognized official slogan or tagline. However, considering their focus, a fitting tagline might be:

• 'Overcoming Resistance, Improving Lives.'
• 'Targeting Resistance, Transforming Cancer Care.'
• 'Innovation in Cancer Resistance.'

To gain more insights into ORIC Pharmaceuticals, Inc. (ORIC) financial standing, consider exploring: Breaking Down ORIC Pharmaceuticals, Inc. (ORIC) Financial Health: Key Insights for Investors

ORIC Pharmaceuticals, Inc. (ORIC) How It Works

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments that overcome resistance mechanisms in cancer. They aim to improve the effectiveness of existing cancer therapies and address unmet needs by targeting these resistance mechanisms.

ORIC Pharmaceuticals' Product/Service Portfolio

ORIC Pharmaceuticals' Operational Framework

ORIC Pharmaceuticals operates through a focused approach to drug development, concentrating on specific mechanisms of cancer resistance. Key aspects of their operational framework include:

• Target Identification and Validation: Identifying and validating novel targets involved in cancer resistance.
• Drug Discovery and Development: Developing small molecule inhibitors and antagonists designed to interact with these targets.
• Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates.
• Partnerships and Collaborations: Collaborating with academic institutions and other companies to advance their research and development efforts.
• Intellectual Property: Protecting their inventions through patents and other intellectual property rights.

ORIC Pharmaceuticals' Strategic Advantages

ORIC Pharmaceuticals has several strategic advantages that contribute to its potential success:

• Targeting Resistance Mechanisms: By focusing on overcoming resistance to existing therapies, ORIC aims to address a critical unmet need in cancer treatment.
• Novel Drug Candidates: Their pipeline includes drug candidates with novel mechanisms of action, potentially offering new treatment options for patients.
• Experienced Management Team: A management team with a proven track record in drug development and commercialization.
• Strong Financial Position: As of the fiscal year 2024, ORIC reported having a solid financial position, with approximately $274.2 million in cash, cash equivalents, and marketable securities. This provides a runway to fund their clinical programs and research activities.

To gain more insights into the investors and stakeholders behind ORIC Pharmaceuticals, explore: Exploring ORIC Pharmaceuticals, Inc. (ORIC) Investor Profile: Who’s Buying and Why?

ORIC Pharmaceuticals, Inc. (ORIC) How It Makes Money

ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, and currently, it does not generate revenue from product sales. Its primary focus is on discovering and developing therapies designed to overcome resistance in cancer. As a clinical-stage company, ORIC's revenue model is centered around securing funding through various means to support its research and development activities.

ORIC Pharmaceuticals, Inc. Revenue Breakdown

As a clinical-stage biopharmaceutical company, ORIC Pharmaceuticals currently generates revenue primarily through collaborations, licensing agreements, and investment income, as detailed in their financial statements. Since ORIC does not have products on the market, it does not generate revenue from product sales.

ORIC Pharmaceuticals, Inc. Business Economics

ORIC Pharmaceuticals' business economics are characterized by high research and development (R&D) costs and a long lead time to potential revenue generation. The company invests heavily in its pipeline of cancer therapies, focusing on novel mechanisms to overcome resistance. Key aspects of its business economics include:

• R&D Investment: A significant portion of ORIC's operating expenses is dedicated to R&D, covering preclinical studies, clinical trials, and drug development activities.
• Partnerships and Licensing: Strategic collaborations and licensing agreements are crucial for funding and accelerating the development process. These partnerships can provide upfront payments, milestone payments, and royalties on future sales.
• Cash Runway: The company's ability to maintain a sufficient cash runway is vital for sustaining operations until it can achieve profitability through commercializing its products or further licensing deals.
• Intellectual Property: Strong patent protection is essential to maintain a competitive advantage and secure future revenue streams.

ORIC Pharmaceuticals, Inc. Financial Performance

ORIC Pharmaceuticals' financial performance reflects its status as a clinical-stage company with substantial R&D expenditures. Here are key points regarding its financial performance:

• Operating Expenses: The company's operating expenses primarily consist of R&D and general and administrative (G&A) costs. R&D expenses include costs associated with clinical trials, preclinical studies, manufacturing, and personnel.
• Net Loss: As a development-stage company, ORIC typically reports a net loss, as it is investing heavily in its pipeline without generating product revenue.
• Cash Position: Maintaining a strong cash position is critical for funding ongoing operations and advancing its clinical programs. ORIC's cash balance is influenced by financing activities, such as equity offerings and collaborations.
• Financial Strategy: The company's financial strategy focuses on managing expenses, securing additional funding through various means, and advancing its pipeline to create long-term value.

To gain more insights into ORIC Pharmaceuticals, Inc., explore: Mission Statement, Vision, & Core Values of ORIC Pharmaceuticals, Inc. (ORIC).

ORIC Pharmaceuticals, Inc. (ORIC) Market Position & Future Outlook

ORIC Pharmaceuticals is strategically positioned to advance its oncology pipeline, with a focus on overcoming resistance mechanisms in cancer treatments. The company's future outlook hinges on the successful development and commercialization of its lead drug candidates and strategic collaborations.

Competitive Landscape

The competitive landscape for ORIC Pharmaceuticals includes major pharmaceutical companies and specialized biotech firms also developing cancer therapies. Market share is dynamic and varies by specific cancer type and treatment modality.

Opportunities & Challenges

Industry Position

ORIC Pharmaceuticals is an emerging player in the oncology space, focusing on developing innovative therapies to combat resistance in cancer treatments. Its industry position can be further described by:

• Pipeline Focus: ORIC is concentrating on a targeted pipeline with novel mechanisms of action.
• Early Stage: As of now, ORIC is largely in the clinical trial phase, setting the stage for potential market entry pending successful trial outcomes and regulatory approvals.
• Strategic Partnerships: Strategic collaborations will be vital for ORIC to expand its capabilities and market reach.

To gain more insight into the company's financial standing, you can explore: Breaking Down ORIC Pharmaceuticals, Inc. (ORIC) Financial Health: Key Insights for Investors